Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Ranibizumab (Primary) ; Tocilizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms READ-4
- 07 Jun 2017 Biomarkers information updated
- 26 Apr 2017 Planned initiation date changed from 1 Feb 2016 to 1 Dec 2017.
- 01 Dec 2015 Planned end date changed from 1 Oct 2017 to 1 Oct 2018, as reported by ClinicalTrials.gov.